Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells (CLONTAK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00224354
Recruitment Status : Withdrawn
First Posted : September 23, 2005
Last Update Posted : May 21, 2012
Sponsor:
Collaborators:
The Methodist Hospital System
Center for Cell and Gene Therapy, Baylor College of Medicine
Information provided by (Responsible Party):
George Carrum, Baylor College of Medicine

Brief Summary:

In the laboratory, we will put a special gene into cancer cells that have been taken from the subject. This gene will make the cells produce interleukin 2 (IL-2), which may help the patient's immune system kill cancer cells. Also, we will use CD40 ligand (CD40L) with the IL-2. Studies of cancers in animals and in cancer cells that are grown in laboratories have suggested adding the CD40L helps the IL-2 work better. Some of these new cells will then be given back to the subject as a vaccine shot.

We believe that a part of the subject's immune system (cells called T-reg cells) might try to kill off these special cells. If the T-reg cells do that, the vaccine would not work as well or last as long. To try to avoid this, before the special cells are put back into the subject's body, we will give them an intravenous (IV) dose of IL-2 immunotoxin (called denileuk diftitox or ONTAK). ONTAK should get rid of some of the T-reg cells in the subject's body which should help the special cells work better and longer.

The purpose of this study is to learn the safety and cancer-fighting effects of using IL-2 with the vaccine.


Condition or disease Intervention/treatment Phase
CHRONIC LYMPHOCYTIC B-LEUKEMIA Biological: IL-2 secreting and hCL4OL-expressing autologous B-CLL cells Biological: IL-2 Biological: CD40L Drug: ONTAK Biological: immunotoxin dose Phase 1

Detailed Description:

This is a phase I trial to assess the safety of depleting regulatory T (Treg) cells using 1-3 doses of an interleukin-2 immunotoxin directed to the CD25 antigen (denileukin diftitox, ONTAK) in chronic lymphocytic leukemia (B-CLL) patients, followed by six subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L). Patients will receive a fixed dose (2 x 10e7) of IL-2 secreting B-cells together with 2 x 10e7 hCD40L expressing B-cells, representing a safe, well tolerated and immunogenic dose in our previous dose escalation study.

All eligible patients will be treated with six injections. Any patient whose disease regresses after the administration of 6 injections may be offered further injections of tumor vaccine if sufficient vaccine is available. There will be no use of placebo or control subjects.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treatment of Chronic Lymphocytic B-Leukemia (B-CLL) With Human IL-2 Gene Modified and Human CD40 Ligand-Expressing Autologous Tumor Cells After Depletion of Regulatory T Cells
Study Start Date : September 2005
Actual Primary Completion Date : December 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine



Intervention Details:
  • Biological: IL-2 secreting and hCL4OL-expressing autologous B-CLL cells
    Patients will be treated with six subcutaneous injections of their IL-2-secreting and hCD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window
  • Biological: IL-2
    subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
  • Biological: CD40L
    subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
  • Drug: ONTAK
    an interleukin-2 immunotoxin directed to the CD25 antigen (denileukin diftitox, ONTAK
  • Biological: immunotoxin dose
    Days 0, 2, and 4 (18 ug/kg) i.v
    Other Name: ONTAK


Primary Outcome Measures :
  1. Safety of (Treg) cells using interleukin-2 immunotoxin directed to the CD25 antigen in(B-CLL) patients, then six (SC) injections of autologous leukemic cells modified to secrete (hIL-2) and to express (hCD40L). [ Time Frame: 15 years ]
  2. To obtain preliminary data on the anti-tumor effects of this treatment regimen. [ Time Frame: 15 years ]

Secondary Outcome Measures :
  1. determine whether MHC-restricted or unrestricted anti-tumor immune responses are induced and sustained by the combination of Treg cell depletion and SC injections of B-CLL cells, which have been modified ex vivo to secrete hIL-2 and to express hCD40L [ Time Frame: 15 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pre Inclusion Eligibility Criteria: Proof of B-CLL diagnosis not in Richter's transformation

Eligibility Criteria:

  • Manipulated B-CLL cells available (at least 6 injections)
  • B-CLL with measurable disease, not in Richter's transformation
  • Life expectancy greater than or equal to 10 weeks
  • ECOG 0-2 (see Section 4.3 of the full protocol for details)
  • Recovered from the toxic effects of all prior chemotherapy
  • Absolute neutrophil count (ANC) greater than or equal to 500/mL
  • Absolute lymphocyte count (ALC) greater than or equal to 200/mL
  • Hemoglobin greater than or equal to 8 g/dL
  • Platelet count greater than or equal to 50,000/mL
  • Total bilirubin less than or equal to 1.5mg/dL -SGOT less than or equal to 2 x Normal
  • Normal PTT -Creatinine less than 3 x Normal (age-related) or Creatinine clearance > 80mg/min/1.73m2
  • Serum albumin level greater than or equal to 3 g/dl
  • Must not have received treatment with other investigational agents within the last 4 weeks
  • Practicing appropriate birth control during the study and for 3 months after the study is concluded.

Exclusion Criteria:

  • Congestive heart failure
  • Significant arrythmia or history of myocardial infarction
  • Active CNS disease or a history of seizure
  • Active infection / receiving antibiotics (other than prophylactic trimethoprim sulfamethoxazole
  • Seropositive for HIV
  • Pregnancy or lactation / will not use birth control methods
  • Autoimmune disease (GvHD, immune thrombocytopenia-ITP or autoimmune hemolytic anemia-AIHA)
  • Receiving immunosuppressive drugs
  • Hypersensitivity to denileukin diftitox or any of its components: diphteria toxin, interleukin-2, or excipients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00224354


Sponsors and Collaborators
Baylor College of Medicine
The Methodist Hospital System
Center for Cell and Gene Therapy, Baylor College of Medicine
Investigators
Layout table for investigator information
Principal Investigator: GEORGE CARRUM, MD Baylor College of Medicine
Study Director: Malcolm K Brenner, MD Baylor College of Medicine

Layout table for additonal information
Responsible Party: George Carrum, Principal Investigator, Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT00224354    
Other Study ID Numbers: 17656
CLONTAK
First Posted: September 23, 2005    Key Record Dates
Last Update Posted: May 21, 2012
Last Verified: May 2012
Keywords provided by George Carrum, Baylor College of Medicine:
LYMPHOCYTIC
B-LEUKEMIA
B-CLL
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Neoplasms by Histologic Type
Neoplasms
Interleukin-2
Denileukin diftitox
Immunotoxins
Antineoplastic Agents
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Immunologic Factors